Intracellular Immunization Against HIV-1 Infection of Human T Lymphocytes: Utility of Anti-Rev Single-Chain Variable Fragments
Authors:
- Minghua ZhuMZMinghua Zhu
- Omar BagasraOBOmar Bagasra
- Roger J. PomerantzRPRoger J. Pomerantz
- 1 December 1995
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 6 (12) , 1561-1573
Abstract
Genetic therapy offers a potentially promising approach with which to combat human immunodeficiency virus type 1 (HIV-1) infections. Several modalities, using protein- and RNA-based systems, have recently been shown to inhibit HIV-1 replication. A single-chain variable fragment (SFv), constructed from the cDNA of a monoclonal antibody to the HTV-1 regulatory protein Rev, has been demonstrated to potently inhibit HIV-1 replication, when expressed intracellularly in an epithelial cell-line (HeLa-CD4). Murine retroviral shuttle vectors, which express the anti-Rev SFv moiety, have now been constructed. HIV-1 infection was dramatically inhibited in human T-lymphocytic cell-lines, CEM and Sup-Tl, transduced with these anti-Rev SFv-expressing vectors. This resistance to high levels of HIV-1 expression was demonstrated in both mixed populations and clones of these cells. Of further potential clinical significance, HIV-1 infection was also potently inhibited in human peripheral blood mononuclear cells (PBMC), transduced with retroviral vectors expressing the anti-Rev SFv molecule. These data suggest that intracellular expression of anti-Rev SFvs, or related approaches, may be utilized as genetic therapy, or intracellular immunization, for HIV-1 infections in vivo. An anti-Rev single-chain variable fragment (SFv) moiety can be efficiently expressed, using murine retroviral vectors, in human T lymphocytic cell lines as well as in primary human blood mononuclear cells (PBMC). Both mixed cellular populations and cell clones, transduced with the anti-Rev SFv, demonstrated significant resistance to productive human immunodeficiency virus type 1 (HIV-1) replication. Thus, intracellular immunization may be approachable, using ex vivo transduction of human cells with anti-Rev SFvs, in HIV-1-infected individuals.Keywords
This publication has 52 references indexed in Scilit:
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Retroviral Transfer of the nlsLacZ Gene into Human CD34 + Cell Populations and into TF-1 Cells: Future Prospects in Gene TherapyHuman Gene Therapy, 1994
- Molecular and Virological Effects of Intracellular Anti-Rev Single-Chain Variable Fragments on the Expression of Various Human Immunodeficiency Virus-1 StrainsHuman Gene Therapy, 1994
- Monoclonal Antibody-Mediated Inhibition of RNA Binding and Annealing Activities of HIV Type 1 Nucleocapsid ProteinAIDS Research and Human Retroviruses, 1994
- Intracellular Expression of Anti-p21ras Single Chain Fv Fragments Inhibits Meiotic Maturation of Xenopus OocytesBiochemical and Biophysical Research Communications, 1993
- Infection of Human Cells with Murine Amphotropic Replication-Competent RetrovirusesHuman Gene Therapy, 1993
- Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial LibrariesJournal of Molecular Biology, 1993
- Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.Journal of Experimental Medicine, 1992
- Intracellular immunizationFEBS Letters, 1990